Literature DB >> 3115109

Toxicity of tumor necrosis factor is synergistic with gamma-interferon and can be reduced with cyclooxygenase inhibitors.

J E Talmadge, O Bowersox, H Tribble, S H Lee, H M Shepard, D Liggitt.   

Abstract

In recent studies, we have demonstrated that recombinant human tumor necrosis factor (rH TNF), as a single agent, has only minimal therapeutic activity for the treatment of metastatic disease, but when combined with recombinant murine gamma-interferon (rM gamma-IFN), we observed significantly more therapeutic activity than when either agent was administered alone. However, this combination also resulted in increased toxicity. Thus, we undertook a systematic toxicologic study of rH TNF alone or in combination with rM gamma-IFN. Briefly, the toxicity was similar to the generalized Shwartzman's reaction seen during endotoxin shock, with multifocal microthrombi and ischemic necrosis as sequelae. Lesions were observed in the lungs, liver, gastrointestinal tract (preferentially in the duodenum and cecum), testes or uterus, and bone marrow. Our results suggest that TNF (either directly administered or induced in situ) and its induction of arachidonic acid metabolites form one element of toxicity in this model. This conclusion is supported by studies revealing that the toxicity of rH TNF in combination with rM gamma-IFN can be reduced by inhibitors of the cyclooxygenase/lipoxygenase pathway.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3115109      PMCID: PMC1899682     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  46 in total

Review 1.  Induction and immunological properties of tumor necrosis factor.

Authors:  M K Hoffmann; H F Oettgen; L J Old; R S Mittler; U Hammerling
Journal:  J Reticuloendothel Soc       Date:  1978-04

2.  In vitro synergism between interferons and human lymphotoxin: enhancement of lymphotoxin-induced target cell killing.

Authors:  T W Williams; J A Bellanti
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

3.  The selection and characterization of an invasive variant of the B16 melanoma.

Authors:  I R Hart
Journal:  Am J Pathol       Date:  1979-12       Impact factor: 4.307

4.  Cytotoxicity mediated by soluble macrophage product(s).

Authors:  K K Sethi; H Brandis
Journal:  J Natl Cancer Inst       Date:  1975-08       Impact factor: 13.506

5.  Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin.

Authors:  F Gonzalez-Crussi; W Hsueh
Journal:  Am J Pathol       Date:  1983-07       Impact factor: 4.307

6.  Cell cycle-specific effects of tumor necrosis factor.

Authors:  Z Darzynkiewicz; B Williamson; E A Carswell; L J Old
Journal:  Cancer Res       Date:  1984-01       Impact factor: 12.701

7.  Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon.

Authors:  B D Williamson; E A Carswell; B Y Rubin; J S Prendergast; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

8.  Generation and characterization of a lipopolysaccharide-induced and serum-derived cytotoxic factor for tumor cells.

Authors:  D N Männel; M S Meltzer; S E Mergenhagen
Journal:  Infect Immun       Date:  1980-04       Impact factor: 3.441

9.  Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cells in vitro.

Authors:  K Haranaka; N Satomi
Journal:  Jpn J Exp Med       Date:  1981-06

10.  Activated macrophages release a factor which lyses malignant cells but not normal cells.

Authors:  G A Currie; C Basham
Journal:  J Exp Med       Date:  1975-12-01       Impact factor: 14.307

View more
  26 in total

1.  Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumour necrosis factor-alpha.

Authors:  L Mahraoui; M Heyman; O Plique; M T Droy-Lefaix; J F Desjeux
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

2.  Immunomodulatory and therapeutic properties of FK-565 in mice.

Authors:  J E Talmadge; B Lenz; M Schneider; H Phillips; C Long
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 3.  Tumor necrosis factor and immunopathology.

Authors:  P F Piguet; G E Grau; P Vassalli
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 4.  The role of OKT3 in clinical transplantation.

Authors:  D J Norman; M R Leone
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

5.  Inter-mouse strain differences in the in vivo anti-CD3 induced cytokine release.

Authors:  C Ferran; M Dy; K Sheehan; S Merite; R Schreiber; P Landais; G Grau; J Bluestone; J F Bach; L Chatenoud
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

6.  Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice.

Authors:  P N Gilles; G Fey; F V Chisari
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

7.  Inhibition of endotoxin-induced interleukin-6 production by synthetic lipid A partial structures in human peripheral blood mononuclear cells.

Authors:  M H Wang; H D Flad; W Feist; H Brade; S Kusumoto; E T Rietschel; A J Ulmer
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

8.  Differential effects of monoclonal antibodies to tumor necrosis factor alpha and gamma interferon on induction of hepatic nitric oxide synthase in experimental gram-negative sepsis.

Authors:  T Evans; A Carpenter; A Silva; J Cohen
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

9.  Evidence that specific high mannose structures directly regulate multiple cellular activities.

Authors:  N Sathyamoorthy; J M Decker; A P Sherblom; A Muchmore
Journal:  Mol Cell Biochem       Date:  1991-04-10       Impact factor: 3.396

10.  Biological activity of toxic shock syndrome toxin 1 and a site-directed mutant, H135A, in a lipopolysaccharide-potentiated mouse lethality model.

Authors:  B G Stiles; T Krakauer; P F Bonventre
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.